0.921

6.46% 0.0559

After Hours: .94 0.019 +2.06%

Tscan Therapeutics Inc (TCRX)

Overview News Price History Financials Discussions Forecast

Tscan Therapeutics Inc stock is traded at $0.921, with a volume of 495.40K. It is up +6.46% in the last 24 hours and down -13.11% over the past month. TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Previous Close:

$0.8651

Open:

$0.8736

24h Volume:

495.40K

Relative Volume:

0.61

Market Cap:

$60.19M

Revenue:

$9.14M

Net Income/Loss:

$-124.31M

P/E Ratio:

-0.9621

EPS:

-0.9573

Net Cash Flow:

$-125.43M

1W Performance:

+8.60%

1M Performance:

-13.11%

6M Performance:

+1.13%

1Y Performance:

-36.48%

1-Day Range:

$0.8736

$0.955

1-Week Range:

$0.85

$0.955

52-Week Range:

$0.8481

$2.57

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Name

Tscan Therapeutics Inc

Sector

Healthcare (1102)

Industry

Biotechnology (619)

Phone

857-399-9500

Address

830 WINTER STREET, WALTHAM

Employee

142

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

TCRX's Discussions on Twitter

Compare TCRX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TCRX Tscan Therapeutics Inc	0.921	60.12M	9.14M	-124.31M	-125.43M	-0.9573
VRTX Vertex Pharmaceuticals Inc	468.42	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	618.03	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.40	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	288.18	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	169.51	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-16-24	Initiated	BTIG Research	Buy
May-13-24	Initiated	Needham	Buy
Jun-22-23	Initiated	Wedbush	Outperform

Tscan Therapeutics Inc Stock (TCRX) Latest News

02:52 AM

H.C. Wainwright reiterates Tscan stock rating on trial data - Investing.com UK

02:52 AM

12:54 PM

TCRX Reiterated by Needham -- Price Target Maintained at $6.00 - GuruFocus

12:54 PM

07:55 AM

H.C. Wainwright reiterates Tscan stock rating on trial data By Investing.com - Investing.com Canada

07:55 AM

07:01 AM

H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7 - Moomoo

07:01 AM

06:53 AM

Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo

06:53 AM

Jun 22, 2026

TScan reports Phase 1 data for TSC-101 blood cancer trial - grafa.com

Jun 22, 2026

Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria

Jun 22, 2026

TScan Therapeutics Advances TSC-101 Toward Pivotal Trial - TipRanks

Jun 22, 2026

TScan reports trial data for blood cancer treatment TSC-101 - Investing.com

Jun 22, 2026

TCRX: Cohort C results support advancing TSC-101 to Phase 3, showing high efficacy and safety - TradingView

Jun 22, 2026

TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial - Stock Titan

Jun 22, 2026

TScan says 11 of 14 patients hit complete donor chimerism after TSC-101 - Stock Titan

Jun 22, 2026

Jun 20, 2026

Number of shareholders of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView

Jun 20, 2026

Jun 17, 2026